2025
All-Cause Mortality is Higher in Generalized Pustular Psoriasis (GPP) than Plaque Psoriasis and the General Population: A US-Based Claims Analysis.
Gottlieb A, Crooke Kwiatkowski H, Semeco J, Lakshminarasimhan B, Strober B, Lebwohl M. All-Cause Mortality is Higher in Generalized Pustular Psoriasis (GPP) than Plaque Psoriasis and the General Population: A US-Based Claims Analysis. Journal Of Psoriasis And Psoriatic Arthritis 2025, 24755303251344155. PMID: 40454110, PMCID: PMC12125009, DOI: 10.1177/24755303251344155.Peer-Reviewed Original ResearchAll-Cause MortalityGeneralized pustular psoriasisMortality riskGeneral populationMaximum follow-upFollow-upElevated mortality riskPlaque psoriasisPustular psoriasisAll-CauseMortality burdenClaims dataDays post-indexIndex dateMedical claimsPopulation of patientsObservational studyUS claims dataUS-basedPropensity score matchingCohortLimited literaturePost-indexBalance covariatesMortalityBimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial
Blauvelt A, Langley R, Lebwohl M, Strober B, Warren R, Puig L, Morita A, Gordon K, Fernandez-Peñas P, Kavanagh S, López Pinto J, Lambert J, Hoepken B, Deherder D, Cross N, Thaçi D. Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. Journal Of The American Academy Of Dermatology 2025 PMID: 40286813, DOI: 10.1016/j.jaad.2025.04.038.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsComplete skin clearanceSkin clearanceAdverse eventsRates of treatment-emergent adverse eventsModerate to severe plaque psoriasisOpen-label extension trialModerate to severe psoriasisLong-term treatment optionUpper respiratory tract infectionSevere plaque psoriasisOpen-label extensionPhase 3 trialRespiratory tract infectionsDurability of efficacyOral candidiasisEnd-of-studyPlaque psoriasisSevere psoriasisTract infectionsLong-term managementBimekizumabSafety profileTreatment optionsImprove patient well-beingDeucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials
Armstrong A, Kircik L, Stein Gold L, Strober B, De Oliveira C, Vaile J, Jou Y, Daamen C, Scharnitz T, Lebwohl M. Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials. Dermatology And Therapy 2025, 15: 1025-1035. PMID: 40113724, PMCID: PMC11971090, DOI: 10.1007/s13555-025-01362-w.Peer-Reviewed Original ResearchLaboratory adverse eventsLaboratory parametersAdverse eventsLong-term extensionPlaque psoriasisModerate to severe plaque psoriasisSevere plaque psoriasisDouble-blind trialTyrosine kinase 2 inhibitorTreatment of adultsJanus kinaseSystemic therapyClinically meaningful changeDeucravacitinibPsoriasis trialsPatientsIncidence rateHigh gradePlaceboApremilastMeaningful changePsoriasisTrialsGradePhase 3Deucravacitinib in Moderate to Severe Plaque Psoriasis: 5-year, Long-term Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials
Armstrong A, Warren R, Strober B, Blauvelt A, Tada Y, Passeron T, Thaçi D, Daamen C, Li J, Popmihajlov Z, Vaile J, Scotto J, Lebwohl M. Deucravacitinib in Moderate to Severe Plaque Psoriasis: 5-year, Long-term Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal Of Cutaneous Medicine 2025, 9: s532. DOI: 10.25251/skin.10.supp.532.Peer-Reviewed Original ResearchLong-term extensionLong-term extension trialsSevere plaque psoriasisPlaque psoriasisLong-term safetyTyrosine kinase 2Moderate to severe plaque psoriasisSafety signalsExposure-adjusted incidence ratesModified nonresponder imputationClinical response rateClinical efficacy rateParent trialYears of continuous treatmentLong-term efficacyYear of treatmentAssess adverse eventsTreatment of adultsOral placeboSystemic therapyNonresponder imputationEfficacy rateTargeted therapySafety profileEfficacy profileDeucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials
Armstrong A, Lebwohl M, Warren R, Sofen H, Morita A, Paul C, Papp K, Colombo M, Scotto J, Vaile J, Zhuo J, Vritzali E, Berger V, Schroeder G, Banerjee S, Thaçi D, Strober B. Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials. Journal Of The European Academy Of Dermatology And Venereology 2025, 39: 1336-1351. PMID: 40045918, PMCID: PMC12188513, DOI: 10.1111/jdv.20553.Peer-Reviewed Original ResearchLong-term extension trialsLong-term extensionModerate to severe plaque psoriasisSevere plaque psoriasisPlaque psoriasisAdverse eventsTyrosine kinase 2Person yearsData cut-offYear of treatmentAdverse cardiovascular eventsTreatment of adultsPatient-reported outcomesSystemic therapyHerpes zosterSafety profileVenous thromboembolismDeucravacitinibCardiovascular eventsEfficacy resultsPatientsPsoriasisOutcome ratesExtension trialParent trialMission impossible? Caveats in interpreting and comparing long‐term efficacy in biologic studies for moderate‐to‐severe plaque psoriasis
Langley R, Egeberg A, Gooderham M, Bissonnette R, Ringuet J, Kalia S, Park‐Wyllie L, Abbarin N, Tran D, Zara A, Yang Y, Strober B. Mission impossible? Caveats in interpreting and comparing long‐term efficacy in biologic studies for moderate‐to‐severe plaque psoriasis. Journal Of The European Academy Of Dermatology And Venereology 2025, 39: e613-e616. PMID: 39985198, DOI: 10.1111/jdv.20555.Peer-Reviewed Original ResearchLong-term efficacyPlaque psoriasisBimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period
Warren R, Lebwohl M, Thaçi D, Gooderham M, Pinter A, Paul C, Gisondi P, Szilagyi B, White K, Deherder D, Staelens F, Lambert J, Strober B. Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period. British Journal Of Dermatology 2025, 193: 44-55. PMID: 39862230, DOI: 10.1093/bjd/ljaf032.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsOpen-label extensionComplete skin clearanceIL-17APlaque psoriasisSkin clearanceIL-17FRates of treatment-emergent adverse eventsTreatment-emergent adverse event ratesModerate to severe plaque psoriasisOpen-label extension periodSafety of bimekizumabUpper respiratory tract infectionDouble-blind periodSevere plaque psoriasisInterleukin (IL)-17ARespiratory tract infectionsYear of treatmentLong-term resultsInflammatory bowel diseaseMonoclonal IgG1 antibodyOral candidiasisClinical responseMaintenance doseTract infectionsSafety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years
Armstrong A, Lebwohl M, Warren R, Sofen H, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Kisa R, Vaile J, Berger V, Vritzali E, Hoyt K, Colombo M, Scotto J, Banerjee S, Strober B, Thaçi D, Blauvelt A. Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years. JAMA Dermatology 2025, 161: 56-66. PMID: 39602111, PMCID: PMC11736510, DOI: 10.1001/jamadermatol.2024.4688.Peer-Reviewed Original ResearchLong-term extension trialsExposure-adjusted incidence ratesSevere plaque psoriasisLong-term extensionModerate to severe plaque psoriasisAdverse eventsPlaque psoriasisDouble-blind phase 3 trialStatic Physician's Global Assessment scoreDiscontinuation due to adverse eventsDay 1Physician Global Assessment scoreIncidence rateEffective long-term treatmentUpper respiratory tract infectionClinical response rateGlobal assessment scorePhase 3 trialRespiratory tract infectionsWeeks of treatmentYear of treatmentLong-term treatmentAdverse cardiovascular eventsLong-term safetyCumulative period
2024
Brodalumab: Six-Year US Pharmacovigilance Report
Lebwohl M, Koo J, Armstrong A, Strober B, Yoon S, Rawnsley N, Goehring E, Mangin G, Jacobson A. Brodalumab: Six-Year US Pharmacovigilance Report. Dermatology And Therapy 2024, 15: 213-222. PMID: 39589679, PMCID: PMC11785849, DOI: 10.1007/s13555-024-01304-y.Peer-Reviewed Original ResearchAdverse eventsSystemic therapyUS patientsCase of Candida infectionSafety profile of brodalumabSafety of brodalumabMajor adverse cardiovascular eventsInterleukin-17 receptorAdverse cardiovascular eventsLong-term safetyFungal infection rateCandida infectionsPlaque psoriasisSafety profileAdult patientsBrodalumabCardiovascular eventsBox warningPharmacovigilance reportsFungal infectionsClinical trialsPatientsPharmacovigilance dataMedDRA QueriesClinical practiceCriteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North America
Strober B, Zhong Y, Sima A, Beeghly A, Eckmann T, Balagula E, Zhuo J, Lebwohl M. Criteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North America. Journal Of Psoriasis And Psoriatic Arthritis 2024, 10: 22-27. PMID: 39583219, PMCID: PMC11583168, DOI: 10.1177/24755303241302070.Peer-Reviewed Original ResearchBody surface areaInternational Psoriasis CouncilSystemic therapySystemic psoriasis treatmentsDisease severity criteriaTopical therapyPsoriasis treatmentTherapy candidatesCorEvitas Psoriasis RegistrySystemic therapy initiationTreatment-naive patientsSeverity criteriaReal-world studyCross-sectional studyDisease severity indicatorsPatient-reported outcome measuresPlaque psoriasisPsoriasis RegistryTherapy initiationSystemic treatmentRegistry visitPASI scoreClinical characteristicsClinical decision-makingPsoriasis severityDeucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials
Armstrong A, Lebwohl M, Warren R, Sofen H, Morita A, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Colombo M, Vaile J, Vritzali E, Hoyt K, Daamen C, Banerjee S, Strober B, Thaçi D, Blauvelt A. Deucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s423. DOI: 10.25251/skin.8.supp.423.Peer-Reviewed Original ResearchAssess adverse eventsLong-term extensionModerate to severe plaque psoriasisExposure-adjusted incidence ratesSevere plaque psoriasisPlaque psoriasisLong-term extension trialsClinical response rateParent trialAdverse cardiovascular eventsTreatment of adultsSystemic therapyEfficacy outcomesHerpes zosterSafety profileVenous thromboembolismAdverse eventsDeucravacitinibEfficacy resultsCardiovascular eventsSafety signalsPatientsResponse rateIncidence ratePsoriasisEvaluation of Changes in Laboratory Parameters from a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Selective TYK2 Inhibitor, in Patients with Moderate-to-Severe Plaque Psoriasis
Gooderham M, Bunick C, Kircik L, Lynde C, Skov L, Blau J, Zhang W, Uy J, Winkelman W, Thaçi D. Evaluation of Changes in Laboratory Parameters from a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Selective TYK2 Inhibitor, in Patients with Moderate-to-Severe Plaque Psoriasis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s442. DOI: 10.25251/skin.8.supp.442.Peer-Reviewed Original ResearchPhase 2b trialLaboratory parametersPlaque psoriasisCommon Terminology Criteria for Adverse Events grade 1Adverse Events grade 1Mild to moderate elevationMean triglyceride valuesPhase 3 studyAssessment of laboratory parametersAssociated with rhabdomyolysisTyrosine kinase 2 inhibitorCreatine kinaseJanus kinaseSerum cholesterol levelsDouble-blindPrimary endpointPsoriasis AreaCK elevationStudy treatmentLipid parametersTriglyceride valuesGrade 1PsoriasisCholesterol levelsPatientsThe Association Between Patient-Reported Disease Burden and Treatment Switching in Patients with Plaque Psoriasis Treated with Nonbiologic Systemic Therapy
Patel V, Park S, Zhong Y, Sima A, Zhuo J, Roberts-Toler C, Becker B, Hovland S, Strober B. The Association Between Patient-Reported Disease Burden and Treatment Switching in Patients with Plaque Psoriasis Treated with Nonbiologic Systemic Therapy. Psoriasis Targets And Therapy 2024, 14: 167-174. PMID: 39624651, PMCID: PMC11610380, DOI: 10.2147/ptt.s478352.Peer-Reviewed Original ResearchPatient-reported disease burdenVisual analog scaleBiologic therapyPlaque psoriasisDisease burdenOdds ratioInitiation of biologic therapyQuality of lifeCorEvitas Psoriasis RegistryNonbiologic systemic therapyDisease severityPatient-reported burdenMultivariate logistic regression modelDermatology Life Quality IndexDays of enrollmentReal-world studyWork Productivity and Activity Impairment QuestionnaireLife Quality IndexPhysician-rated disease severityTherapy-naiveBiologic-naiveHealth-related quality of lifePsoriasis RegistrySystemic therapySkin painMatching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
Armstrong A, Soliman A, Gisondi P, Fang S, Patel M, Strober B. Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis. Dermatology And Therapy 2024, 14: 3071-3081. PMID: 39453596, PMCID: PMC11557788, DOI: 10.1007/s13555-024-01293-y.Peer-Reviewed Original ResearchDermatology Life Quality IndexSkin clearanceIndirect comparisonsStatic Physician's Global AssessmentRisankizumab-treated patientsPhysician global assessmentTreatment of psoriasisMatching-adjusted indirect comparisonIndividual patient dataLife Quality IndexPlaque psoriasisPsoriasis AreaRisankizumabDeucravacitinibNew therapiesIntroductionDespite advancesPsO.Global assessmentQuality of lifePsoriasisPatientsPropensity scorePatient dataClearanceHealthcare providers52671 Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Gordon K, Thaçi D, Gooderham M, Okubo Y, Strober B, Peterson L, Deherder D, Pinto J, Gisondi P. 52671 Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials. Journal Of The American Academy Of Dermatology 2024, 91: ab145. DOI: 10.1016/j.jaad.2024.07.577.Peer-Reviewed Original Research52675 Bimekizumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Pooled analysis from up to 3 years of treatment in 5 phase 3/3b clinical trials
Strober B, Krueger J, Magnolo N, Vender R, Boehncke W, Hong H, Tilt N, Staelens F, Wiegratz S, Paul C. 52675 Bimekizumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Pooled analysis from up to 3 years of treatment in 5 phase 3/3b clinical trials. Journal Of The American Academy Of Dermatology 2024, 91: ab142. DOI: 10.1016/j.jaad.2024.07.572.Peer-Reviewed Original ResearchBimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3/3b Clinical Trials
Gordon K, Thaçi D, Gooderham M, Okubo Y, Strober B, Peterson L, Deherder D, López Pinto J, Gisondi P. Bimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3/3b Clinical Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s404. DOI: 10.25251/skin.8.supp.404.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsSevere plaque psoriasisOpen-label extensionPlaque psoriasisOral candidiasisPatient yrModerate to severe plaque psoriasisUpper respiratory tract infectionLong-term safety of treatmentRespiratory tract infectionsNext scheduled visitYear of treatmentSafety of treatmentLong-term safetySafety findingsTract infectionsLong-term managementBimekizumabSafety profileAdverse eventsPooled analysisClinical trialsQ8WSafety dataPsoriasisDeucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials
Armstrong A, Lebwohl M, Warren R, Sofen H, Morita A, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Colombo M, Vaile J, Vritzali E, Hoyt K, Daamen C, Banerjee S, Strober B, Thaçi D, Blauvelt A. Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s406. DOI: 10.25251/skin.8.supp.406.Peer-Reviewed Original ResearchAssess adverse eventsLong-term extensionModerate to severe plaque psoriasisExposure-adjusted incidence ratesSevere plaque psoriasisPlaque psoriasisLong-term extension trialsClinical response rateTreatment of adultsSystemic therapyEfficacy outcomesHerpes zosterSafety profileVenous thromboembolismAdverse eventsDeucravacitinibEfficacy resultsSafety signalsPatientsContinuous treatmentResponse rateIncidence rateParent trialPsoriasisAllosteric TYK2 inhibitorDeucravacitinib in Plaque Psoriasis: Maintenance of Response Over 4 Years in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials
Strober B, Imafuku S, Paul C, Gooderham M, Spelman L, Seo S, Passeron T, Hoyt K, Colombo M, Banerjee S, Augustin M, Stein Gold L, Alexis A, Thaci D, Lebwohl M, Issa N, Cameron M. Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 4 Years in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s407. DOI: 10.25251/skin.8.supp.407.Peer-Reviewed Original ResearchLong-term extensionModerate to severe plaque psoriasisSevere plaque psoriasisPlaque psoriasisLong-term extension trialsResponse rateModified nonresponder imputationMaintenance of responseYears of continuous treatmentPhase 3 trialLong-term efficacyNonresponder imputationPrimary endpointPsoriasis AreaResponse assessmentClinical efficacyDeucravacitinibPASISafety signalsTreatment durabilityPatientsContinuous treatmentPsoriasisLong-term effectsParent trialRapid Remission of Plaque Psoriasis With Bimekizumab Treatment.
Abdin R, Gharib R, Bunick C, Issa N. Rapid Remission of Plaque Psoriasis With Bimekizumab Treatment. Journal Of Drugs In Dermatology 2024, 23: 694-696. PMID: 39093648, DOI: 10.36849/jdd.8381.Peer-Reviewed Original ResearchConceptsPlaque psoriasisIL-17AIL-17FAnti-IL-17 biologicsSafety of bimekizumabPathogenesis of psoriasisMonoclonal immunoglobulin G1Psoriasis patientsBimekizumabTreatment optionsClinical trialsPsoriasisMedical literatureClearance timeImmunoglobulin G1Rapidity of responseTreatmentPatientsEfficacyClearancePlaqueBrodalumabCytokinesPathogenesisReceptors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply